The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation (NETRF) has awarded $2.62 million in grants to advance research aimed at finding new and innovative treatments for neuroendocrine tumors
COVID forced NETRF’s annual Research Symposium to be held as a virtual meeting in November. Despite this change, the Symposium reached more researchers than ever
Early NETRF-funded research identifies a potential prognostic biomarker to help physicians predict neuroendocrine cancer outcomes.
NETRF’s Director of Research John Kanki, PhD, provides an update on the status of ongoing NETRF-funded research studies during COVID-19.
NETRF-funded research of miniature replicas of human organs is recognized with a Presidential Award for Basic Science at ENETS, a leading international meeting of NET scientists.
NETRF reports progress in the development of neuroendocrine tumor cell lines to help eliminate a decades-old obstacle in laboratory research. To stimulate progress in NET cell lines, NETRF established a Cell Line Prize, funded cell line research, and launched a collaboration with a nationally known research institute. Each of these initiatives has succeeded in establishing NET cell lines.
NETRF welcomes five new members to its Board of Scientific Advisors, a volunteer council of highly distinguished medical and research leaders who share NETRF’s commitment to advancing the diagnosis and treatment of neuroendocrine cancer.
Research to Advance Neuroendocrine Tumor Treatment The Neuroendocrine Tumor Research Foundation (NETRF) today announced $3.5 million in neuroendocrine tumor (NET) research grants to fund 12
A NETRF-funded clinical trial looks at a cancer vaccine called SurVaxM in neuroendocrine cancer to help slow or stop the spread of neuroendocrine tumors.
Highlights from NANETS 2019 symposium where leading NET experts presented progress and identified priorities for moving NET knowledge and care forward.
